Monitoring the response to antituberculosis (anti-TB) treatment can be difficult in patients with tuberculoma. We have retrospectively assessed the ability of F-18 fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) to evaluate the response to anti-TB treatment in patients with tuberculoma.